BARDA grants $30m to advance NewLink/Merck Ebola vaccine
This article was originally published in Scrip
Executive Summary
NewLink Genetics and its partner Merck have been awarded $30m from the US Biomedical Advanced Research and Development Authority (BARDA) to support the manufacturing and development activities of their investigational vaccine rVSV-EBOV against Ebola, which has infected more than 19,300 people, killing over 7,500.